Phenotypic Consequences of <i>SLC25A40-ABCB1</i> Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

Phenotypic Consequences of <i>SLC25A40-ABCB1</i> Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1–2 years of treatment. We previously identified the most common mechanism of acquired resistance in HGSOC to date, transcripti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kathleen I. Pishas, Karla J. Cowley, Ahwan Pandey, Therese Hoang, Jessica A. Beach, Jennii Luu, Robert Vary, Lorey K. Smith, Carolyn E. Shembrey, Nineveh Rashoo, Madelynne O. White, Kaylene J. Simpson, Andrea Bild, Jason I. Griffiths, Dane Cheasley, Ian Campbell, David D. L. Bowtell, Elizabeth L. Christie
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
<i>ABCB1</i>
high-grade serous ovarian cancer
drug resistance
high-throughput drug screening
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/91d80e9c900e4f8aad1cb5d9d14cd353
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/91d80e9c900e4f8aad1cb5d9d14cd353

Ejemplares similares